Please login to the form below

Not currently logged in
Email:
Password:

Insmed

This page shows the latest Insmed news and features for those working in and with pharma, biotech and healthcare.

Insmed claims first FDA okay for limited population antibiotic

Insmed claims first FDA okay for limited population antibiotic

Insmed claims first FDA okay for limited population antibiotic. Arikayce is cleared to treat lung disease caused by MAC. ... Insmed’s Arikayce has become the first antibiotic to be approved under a new FDA pathway that aims to encourage the develop of

Latest news

  • Features Archive listing

    Insmed’s Olaf Bartsch tells PME about the US biotech’s year of progress. .

  • Survival strategy

    Examples include Merck's $130m acquisition of Insmed's biologic facilities and pipeline, Mylan's deal with Biocon in 2009, Pfizer's $350m deal with Biocon for insulin biosimilars in October

  • Biogen Idec gains ALS drug

    In addition, under an FDA-approved programme, a limited number of people with ALS receive Insmed's Iplex, although the drug has not been granted marketing approval for the indication.

  • Biologics at forefront

    Novartis/Sandoz is already a major player in biosimilars while, last year, Merck acquired Insmed's portfolio of follow-on biologics for $130m in cash.

  • The Pump House

    Hepatitis. China. Mecasermin rinfabate. Iplex (Insmed). Growth disorders. US. Methylphenidate. Methylin Chewable Tablets (Alliant Pharmaceuticals).

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Significant figures Significant figures

    Significant figures. Insmed’s Olaf Bartsch tells PME about the US biotech’s year of progress. ... However, Insmed believes ALIS “has the opportunity to dramatically improve the treatment of NTM lung disease”.

  • Deal Watch October 2016 Deal Watch October 2016

    In the deal with Insmed the molecule is in phase I and has been licensed for development and commercialisation in an orphan indication to Insmed and AstraZeneca has retained the option ... 160. AstraZeneca (UK). Insmed. Licence. Dipeptidyl peptidase one

More from intelligence
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health

Cello Health’s mission is to help our clients unlock the potential that exists with their assets, brands and organisations in...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics